...
首页> 外文期刊>EFSA Journal >Nutrimune and immune defence against pathogens in the gastrointestinal and upper respiratory tracts: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No?1924/2006
【24h】

Nutrimune and immune defence against pathogens in the gastrointestinal and upper respiratory tracts: evaluation of a health claim pursuant to Article 14 of Regulation (EC) No?1924/2006

机译:胃肠道和上呼吸道中病原体的营养和免疫防御:根据法规(EC)第1924/2006号第14条评估健康声明

获取原文

摘要

Following an application from H.J. Heinz Supply Chain Europe B.V. submitted for authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of the Netherlands, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Nutrimune and immune defence against pathogens in the gastrointestinal (GI) tract and upper respiratory tract (URT). The food Nutrimune (a pasteurised cow's skim milk fermented with Lactobacillus paracasei CBA L74) which is the subject of the health claim is sufficiently characterised. The Panel considers that immune defence against pathogens in GI tract and URT is a beneficial physiological effect. Two human intervention studies were submitted as being pertinent to the claim, which were evaluated by the Panel in the previous application. One human intervention study from which conclusions could be drawn showed an effect of Nutrimune on immune defence against pathogens in the GI tract and the URT. The post hoc re‐analysis of the two human studies combined does not address the methodological limitations of the second study raised in the previous opinion, i.e. that the study was not planned, designed, randomised and analysed as a multicentre study, and that the large disparity of subjects in the three centres was not duly justified. The results from one animal study could support an effect of Nutrimune on defence against pathogens in the GI tract. No evidence was provided for a plausible mechanism by which Nutrimune could exert the claimed effect in vivo in humans. The Panel concludes that the evidence provided is insufficient to establish a cause and effect relationship between the consumption of Nutrimune and immune defence against pathogens in the GI tract and URT.
机译:根据HJ Heinz欧洲供应链有限公司(BJV)根据1924/2006号法规(EC)第14条通过荷兰主管当局提交的健康要求授权申请,EFSA营养,新型食品和食品过敏原专家小组( NDA被要求就与营养有关的健康主张以及针对胃肠道(GI)和上呼吸道(URT)的病原体的免疫防御提出科学依据。食品Nutrimune(用副干酪乳杆菌CBA L74发酵的巴氏消毒的脱脂牛奶)具有足够的健康特征。专家小组认为,对胃肠道和URT中病原体的免疫防御是有益的生理作用。提交了与索赔有关的两项人为干预研究,小组在先前的申请中对它们进行了评估。一项可以得出结论的人类干预研究表明,营养素对胃肠道和URT中病原体的免疫防御具有一定的作用。两项人类研究相结合的事后重新分析并未解决先前观点提出的第二项研究的方法学局限性,即该研究未计划,设计,随机化和分析为一项多中心研究,这三个中心的科目差异并没有充分的理由。一项动物研究的结果可能支持营养素对胃肠道病原体防御的作用。没有证据表明营养素可以在人体内发挥所要求的作用。专家小组的结论是,所提供的证据不足以在食用营养素与胃肠道和URT病原体的免疫防御之间建立因果关系。

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号